Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31140773 | 0.87 | MAPT (0.58) | MAPTGAAKDM4ELMNATSHR | |
| SCHEMBL23527069 | 0.87 | MAPT (0.58) | MAPTGAAKDM4ELMNATSHR | |
| SCHEMBL23527277 | 0.86 | GAA (0.61) | MAPTGAAKDM4ELMNATSHR | |
| SCHEMBL23527345 | 0.85 | PTGES (0.53) | MAPTGAAKDM4ELMNATSHR | |
| SCHEMBL23527338 | 0.85 | PTGES (0.59) | MAPTGAAKDM4ELMNATSHR | |
| SCHEMBL23527284 | 0.84 | ALPG (0.63) | MAPTGAAKDM4ELMNAPOLB | |
| SCHEMBL23527347 | 0.82 | NPC1 (0.55) | MAPTGAALMNATSHRPOLB | |
| SCHEMBL31140794 | 0.82 | ALDH1A1 (0.52) | MAPTGAAKDM4ELMNAPOLB | |
| SCHEMBL31140790 | 0.82 | NPC1 (0.55) | MAPTGAALMNATSHRPOLB | |
| SCHEMBL14478829 | 0.82 | LMNA (0.63) | MAPTGAAKDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STINGINN LLC (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4075980-B1 | SUBSTITUTED 1,2, 4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163005-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-12134605-B2 | Substituted 1,2,4-triazoles and methods of use | STINGINN, LLC (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240262796-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2024-08-08 | — | — | US | disclosed |
| US-20210188786-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188786-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2021127282-A1 | SUBSTITUTED 1,2, 4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188786-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STING1, IRF3, CGAS | MAPT 4824/4885GAA 683/4885KDM4E 1857/4885 |
| US-12134605-B2 | Substituted 1,2,4-triazoles and methods of use | STING1, IRF3, CGAS | MAPT 4824/4885GAA 683/4885KDM4E 1857/4885 |
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STING1, IRF3, MAVS | MAPT 4720/4885GAA 1548/4885KDM4E 4080/4885 |
| US-20250163005-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STING1, IRF3, CGAS | MAPT 4824/4885GAA 683/4885KDM4E 1857/4885 |
| US-20240262796-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STING1, IRF3, CGAS | MAPT 4824/4885GAA 683/4885KDM4E 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.